Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer

Basit Öğe Kaydı
dc.contributor.authorShahbazi, Reza
dc.contributor.authorAsik, Elif
dc.contributor.authorKahraman, Nermin
dc.contributor.authorTurk, Mustafa
dc.contributor.authorOzpolat, Bulent
dc.contributor.authorUlubayram, Kezban
dc.date.accessioned2020-06-25T18:22:50Z
dc.date.available2020-06-25T18:22:50Z
dc.date.issued2017
dc.departmentKırıkkale Üniversitesi
dc.descriptionShahbazi, Reza/0000-0002-0816-0733
dc.description.abstractAim: In this study, we aimed to therapeutically target eukaryotic elongation factor 2 kinase (eEF-2K) in an in vivo triple-negative breast cancer (TNBC) tumor model. Materials & methods: We synthesized a highly monodisperse nanoformulation using polyethylenimine-modified gold nanoparticles (AuNP-PEI) as siRNA delivery vehicle and evaluated gene downregulation. Results: We found that AuNP-PEI/eEF-2K nanoformulation was highly effective for in vitro and in vivo gene downregulation and showed remarkable antitumor efficacy that was associated with eEF-2K knockdown, inhibition of Src and MAPK-ERK signaling pathways in a TNBC orthotopic tumor model. Conclusion: Our study suggests that eEF-2K plays an important role in TNBC tumorigenesis and its inhibition by AuNP-PEI/eEF-2K siRNA-based nanotherapeutics may be a potential therapeutic strategy for TNBC.en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUBITAK-BIDEB)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [2215]en_US
dc.description.sponsorshipThis research was supported by the Scientific and Technological Research Council of Turkey (TUBITAK-BIDEB) 2215 scholarship program. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.2217/nnm-2017-0081
dc.identifier.endpage1973en_US
dc.identifier.issn1743-5889
dc.identifier.issn1748-6963
dc.identifier.issue16en_US
dc.identifier.pmid28745127
dc.identifier.scopus2-s2.0-85026767955
dc.identifier.scopusqualityQ1
dc.identifier.startpage1961en_US
dc.identifier.urihttps://doi.org/10.2217/nnm-2017-0081
dc.identifier.urihttps://hdl.handle.net/20.500.12587/6928
dc.identifier.volume12en_US
dc.identifier.wosWOS:000406812700005
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherFuture Medicine Ltden_US
dc.relation.ispartofNanomedicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjecteEF2Ken_US
dc.subjecteEF-2K siRNAen_US
dc.subjecteukaryotic elongation factor 2 kinaseen_US
dc.subjectnanotherapeuticsen_US
dc.subjectPEI-modified gold nanoparticlesen_US
dc.subjecttriple-negative breast canceren_US
dc.titleModified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast canceren_US
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu